



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad-500 033. INDIA.
Tel : +91 40 23547532, Fax : +91 40 23548243

July 15, 2014

Corporate Relationship Department
The Bombay Stock Exchange Limited
Dalal Sreet, Fort
Mumbai 400 001

The Manager – Listing
M/s. National Stock Exchange of India Ltd
“Exchange Plaza”, Bandra – Kurla Complex
Bandra (E) Mumbai 400 051

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir

Please find enclose herewith the Press Release for your information.

Thanking you

Yours faithfully
For NATCO Pharma Limited

M Adinarayana
Company Secretary &
Vice President (Legal & Corp Affairs)



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad-500 033. INDIA.
Tel : +91 40 23547532, Fax : +91 40 23548243

Ref:PR/07/2014

Press Release

**Natco pleased with Bombay High Court decision to uphold
Compulsory License on Nexavar issued to the Company**

Hyderabad, India, July 15th, 2014

Natco is pleased to inform that the Bombay High Court upheld the compulsory license (CL) granted to the Company on Nexavar (sorafenib tosylate) of German drug Major Bayer's patented kidney cancer drug.

The Nexavar issue dates back to March 9, 2012, when the then Controller General of Patents issued the first-ever CL to the Company to manufacture an affordable generic version of sorafenib tosylate, the anti-cancer drug for which Bayer had obtained a patent.

Forwarded for favor of publication

For NATCO Pharma Limited

A handwritten signature in black ink, appearing to read "M Adinarayana".

**M Adinarayana
Company Secretary &
Vice President (Legal & Corp. Affairs)**